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Introduction: Hyponatremia is a marker of poor prognosis in patients with cirrhosis. This analysis aimed to assess if
hyponatremia also has prognostic value in patients with acute-on-chronic liver failure (ACLF), a syndrome characterized
by acute decompensation of cirrhosis, organ failure(s) and high short-term mortality.
Methods: We performed an analysis of the Chronic Liver Failure Consortium CANONIC database in 1,341 consecutive
patients admitted to 29 European centers with acute decompensation of cirrhosis (including ascites, gastrointestinal
bleeding, hepatic encephalopathy, or bacterial infections, or any combination of these), both with and without
associated ACLF (301 and 1,040 respectively).
Results: Of the 301 patients with ACLF, 24.3% had hyponatremia at inclusion compared to 12.3% of 1,040 patients
without ACLF (P <0.001). Model for end-stage liver disease, Child-Pugh and chronic liver failure-SOFA scores were
significantly higher in patients with ACLF and hyponatremia compared to those without hyponatremia. The
presence of hyponatremia (at inclusion or during hospitalization) was a predictive factor of survival both in
patients with and without ACLF. The presence of hyponatremia and ACLF was found to have an independent
effect on 90-day survival after adjusting for the potential confounders. Hyponatremia in non-ACLF patients nearly
doubled the risk (hazard ratio (HR) 1.81 (1.33 to 2.47)) of dying at 90 days. However, when considering patients with
both factors (ACLF and hyponatremia) the relative risk of dying at 90 days was significantly higher (HR 6.85 (3.85 to
12.19) than for patients without both factors. Patients with hyponatremia and ACLF had a three-month transplant-free
survival of only 35.8% compared to 58.7% in those with ACLF without hyponatremia (P <0.001).
Conclusions: The presence of hyponatremia is an independent predictive factor of survival in patients with ACLF. In
cirrhosis, outcome of patients with ACLF is dependent on its association with hyponatremia.Introduction
Patients with advanced cirrhosis commonly develop a
functional renal impairment that render the kidney sus-
ceptible to retain sodium and solute-free water. In some
patients, there is disproportionate retention of water rela-
tive to sodium, which leads to a dilutional state where
water is retained out of proportion to sodium causing* Correspondence: pgines@clinic.ub.es
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unless otherwise stated.hyponatremia and hypoosmolality. Although hyponatre-
mia in patients without end-stage liver disease is defined
by serum sodium concentration <135 mEq/L, in cirrhosis
it is defined as a serum sodium concentration of less than
130 mEq/L in the presence of ascites or edema [1-3]. In
the majority of patients hyponatremia occurs in close as-
sociation with an impairment of renal function and corre-
lates with poor prognosis. In patients with cirrhosis and
ascites, the five-year probability of developing hyponatre-
mia is 37% with a 25% probability of survival at one year
[4]. Hyponatremia is also an important marker of progno-
sis in patients with cirrhosis awaiting liver transplantationThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
C?rdenas et al. Critical Care 2014, 18:700 Page 2 of 8
http://ccforum.com/content/18/6/700and may be associated with an increased morbidity, par-
ticularly neurological complications, and reduced survival
after transplantation [5-10].
Despite the fact that there is ample data on the relation-
ship and clinical outcomes between serum sodium,
hyponatremia, and decompensated cirrhosis, there is no
specific information on the frequency, characteristics, and
clinical impact of hyponatremia in patients with acute-on-
chronic liver failure (ACLF). ACLF is considered a syn-
drome that occurs in patients with chronic liver disease,
with or without previously diagnosed cirrhosis, which is
characterized by acute hepatic decompensation resulting
in liver failure (jaundice and prolongation of the inter-
national normalized ratio (INR)) and one or more extra-
hepatic organ failures that is associated with increased
mortality within a period of 28 days and up to three
months from onset [11,12]. The chronic liver failure
(CLIF) consortium recently refined the definition of ACLF
on the basis of a large prospective, multicenter, observa-
tional study [13]. In the study, the overall prevalence of
ACLF was 30.9% with a 90-day mortality rate of 49% [13].
Among the many variables analyzed as risk factors in rela-
tion to the six organ systems (liver, kidney, brain, coagula-
tion, circulation and lungs) included in the modified
sequential organ failure assessment (SOFA) score (CLIF-
SOFA), ascites, and a high leukocyte count were found to
be predictive for the development of ACLF and ACLF-
associated mortality. Serum sodium or hyponatremia were
independent variables that did not make it into the defin-
ition. Serum sodium (but not hyponatremia) has been in-
cluded as a mortality predictor in a CLIF-Consortium
score derived to predict mortality in patients with and
without ACLF (CLIF-C- ACLF score) [14]. Despite these
findings it is not well known if the presence of hyponatre-
mia, a strong prognostic factor in patients with cirrhosis,
influences the outcome of patients with ACLF. Therefore
the aim of this analysis was to determine the specific ef-
fects of hyponatremia on the outcome of patients with
ACLF.
Methods
Study population and data collection
This report represents an analysis of patients enroled in
the Acute-on-Chronic Liver Failure (ACLF) in Cirrhosis
(CANONIC) study from the CLIF consortium, which de-
fined specific criteria for ACLF in cirrhosis [13]. ACLF
was defined as an acute hepatic decompensation resulting
in liver failure (jaundice and prolongation of the INR) and
one or more extrahepatic organ failures in patients with
chronic liver disease with or without previously diagnosed
cirrhosis. In the CANONIC study, patients with cirrhosis
hospitalized with an acute decompensation (AD) (ascites,
gastrointestinal bleeding, hepatic encephalopathy, or
bacterial infections, or any combination of these) werescreened and enroled from February to September 2011
in twenty-nine University Hospitals from eight European
countries. A separate Institutional Review Board approval
was obtained from the original study sites (see link avail-
able at the end of the manuscript, which includes all the
International Review Boards that approved the study at
the various centers involved). Written informed consent
was obtained from patients or their legal surrogates before
inclusion. Data regarding history (including previous epi-
sodes of AD), physical examination, laboratory tests, and
potential precipitating factors of ACLF were recorded. Po-
tential precipitating factors included active alcoholism,
gastrointestinal hemorrhage, bacterial infection, thera-
peutic paracentesis without use of intravenous albumin,
transjugular intrahepatic portosystemic shunting, major
surgery, and acute hepatitis.
Patients with cirrhosis admitted to the hospital with
an AD were enroled in the CANONIC study according
to the definition criteria of ACLF. Patients with two or
more organ/system failures or those with a single renal
failure (serum creatinin ≥ 2 mg/dL) or one or other
organ/system failure in combination with renal insuffi-
ciency (serum creatinine between 1.5 and 1.9 mg/dL) or a
1 to 2 hepatic encephalopathy grade (West Haven scale)
were found to have a poor short-term prognosis and were
consequently assumed to present an ACLF episode [13].
Although hyponatremia in the general population is de-
fined as a serum sodium ≤135 mEq/L, in cirrhosis
current guidelines and consensus define it as a serum
sodium level <130 mEq/L [1,2]. Thus, in this analysis hypo-
natremia was defined as a serum sodium level <130
mEq/L. Patients with hyponatremia at inclusion or who de-
veloped it during hospitalization were managed with fluid
restriction between 1 to 1.5 liters per day according to
current guidelines [2].
Statistical analysis
Data were summarized by means of the appropriate de-
scriptive statistics (means and standard deviation (SD) for
continuous variables, frequencies and percentages for
categorical parameters). Univariate analyses included
Student ? s t test or Mann-Whitney U test for parametric
or nonparametric pairwise comparisons, respectively,
and chi-square tests for categorical variables. Survival
curves were estimated by means of the Kaplan-Meier
method and compared through the log-rank test. The
main study objective was that of assessing the relationship
of ACLF and hyponatremia (and their combination) with
90-day mortality. Those risk factors showing a significant
association with both ACLF and the presence of hypona-
tremia were taken into account as potential confounders
to adjust the effect of ACLF and hyponatremia on 90-day
mortality. Baseline variables associated with ACLF, hypo-
natremia, and 90-day mortality (that is serum creatinine,
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definition of ACLF, so they were not considered as po-
tential confounders in the multivariate modeling. A
proportional hazards model adjusting for these poten-
tial confounders and considering liver transplantation
as a competing risk was fitted to assess the interaction
between ACLF and hyponatremia. A statistically signifi-
cant interaction (P <0.05) would lead to estimation of the
effect of ACLF on mortality separately for each subset of
patients with or without hyponatremia. In the absence of
a significant interaction, the combination of the independ-
ent effects of ACLF and hyponatremia could be estimated
through the model. Potential confounders were kept in
the final model to adjust the combined effect of hypona-
tremia and ACLF only if they led at least to a 10% change
in model coefficients estimated for the two main factors
and their interaction. In all statistical comparisons, a 0.05
significance level (two-tailed) was assumed.Results
Characteristics of the study population
The prevalence of hyponatremia in patients with and
without ACLF is summarized in Figure 1. Mean serum so-
dium concentration in patients with hyponatremia was
125 ? 4 mEq/L compared to 137 ? 4 mEq/L in patients
without hyponatremia (P <0.001). Patients with hypona-
tremia had higher frequency of bacterial infections, asci-
tes, and hepatic encephalopathy at admission. Moreover,
patients with hyponatremia showed signs of more ad-
vanced cirrhosis compared to patients without hyponatre-
mia and, in addition, leukocyte count and C-reactive
protein (CRP) levels were also higher in patients with
hyponatremia (Table 1).All pati
N=1,3
ACLF at enrolment
N=301
(22.5%)
Hyponatremia
N=73 (24.3%)
No Hyponatremia
N=228 (75.7%)
Figure 1 Algorithm of all patients enroled and categorized by the pre
the subsequent development of hyponatremia after inclusion.Relationship between hyponatremia and acute-on-chronic
liver failure
ACLF was more prevalent in patients with hyponatremia
(36.6% vs 20%, P <0.001) (Table 1). When patients with
ACLF at inclusion were categorized according to presence
or absence of hyponatremia those with hyponatremia and
ACLF showed a greater impairment of liver tests (serum
bilirubin and aspartate transaminase (AST) levels), higher
serum creatinine, higher potassium levels, and higher
model for end-stage liver disease (MELD) and Child-Pugh
scores than their nonhyponatremic counterparts (Table 2).
Moreover, CLIF-SOFA score, a score that evaluates the se-
verity of cirrhosis by assessing the function of six different
organs and correlates with prognosis [15], was higher in
patients with ACLF and hyponatremia compared to those
with ACLF without hyponatremia. Interestingly, leukocyte
count was higher in patients with hyponatremia compared
to that of patients without hyponatremia, despite a similar
frequency of bacterial infections in the two groups
(Table 2). In fact, while differences of leukocyte count in
infected patients with or without hyponatremia were not
significantly different, patients with hyponatremia with-
out bacterial infection (n = 46) had significantly higher
leukocyte count than patients without hyponatremia (n =
156) without bacterial infection (11,300 ? 5,700 vs. 8,800 ?
5,000, respectively, P = 0.0062).Effects of hyponatremia and ACLF on survival
At 90 days of follow-up, 264 of the 1,341 patients had died
(19.7%), 961 (71.7%) were alive and 116 (8.7%) had been
transplanted. The presence of hyponatremia (either at in-
clusion or during hospitalization) was a predictive factor
of survival both in patients with and without ACLF.ents
41
No ACLF at enrolment
N=1,040
(77.5%)
Hyponatremia
N=128 (12.3%)
No Hyponatremia
N=912 (87.7%)
sence of acute-on-chronic liver failure (ACLF) at inclusion and
Table 1 Characteristics of all patients according to presence of hyponatremia at study enrolment
Patients? characteristics Patients without hyponatremia
(Na > = 130 mEq/L)
Patients with hyponatremia
(Na <130 mEq/L)
P value
(N = 1140) (N = 201)
Age (years) 57.2 (12.3) 56.7 (11.5) 0.60
Male sex 724 (63.5) 125 (62.2) 0.72
Alcoholic cirrhosis 550 (48) 108 (53) 0.17
Previous decompensations* 794 (72.6) 149 (77.6) 0.15
Complications at admission**
Bacterial infections 264 (23.2) 60 (29.9) 0.04
Hepatic encephalopathy 373 (32.7) 86 (43.0) 0.005
Ascites 738 (65.1) 154 (77.4) <0.001
Gastrointestinal bleeding 208 (18.3) 13 (6.5) <0.001
ACLF 228 (20%) 73 (36.3%) <0.001
Clinical and laboratory data
Mean arterial pressure (mm/Hg) 84 (12.3) 80 (11.9) <0.001
Heart rate (beats/min) 81 (16.2) 84 (16.3) 0.02
Serum bilirubin (mg/dL) 5.7 (7.4) 9.2 (9.5) <0.001
International normalized ratio 1.6 (0.6) 1.8 (0.7) <0.001
AST (U/L) 96 (158) 153 (282) 0.01
ALT (U/L) 56 (129) 71 (110) 0.12
GGT (U/L) 168 (278) 176 (240) 0.69
Serum creatinine (mg/dL) 1.2 (0.9) 1.7 (1.4) <0.001
Serum sodium (mEq/L) 137 (4.1) 125 (4.3) <0.001
Serum potassium (mEq/L) 4.1 (0.7) 4.5 (0.9) <0.001
Leukocyte count (?10 9 cells/L) 7.1 (4.6) 10.1 (6.0) <0.001
Plasma C-reactive protein (mg/L) 29.9 (36.7) 36.4 (32.0) 0.03
MELD score 18.0 (7.1) 22.6 (8.3) <0.001
Child-Pugh score 9.5 (2.1) 10.7 (2.1) <0.001
Data are means (standard deviation (SD)) or number of patients (%). *In the three months prior to study inclusion; **between hospital admission and study
inclusion. ACLF: acute-on-chronic liver failure; AST: aspartate transaminase; ALT: alanine transaminase; GGT: gamma-glutamyl transferase; MELD: model for end-stage
liver disease.
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ciated with both hyponatremia and/or ACLF (Tables 1
and 2) and, at the same time, some were found to be
predictors of 90-day mortality: age, presence of ascites
and bacterial infections, mean arterial pressure, heart
rate, serum potassium and white cell count. All these
variables were taken into account as potential con-
founders for adjusted estimates of the effects of ACLF
and hyponatremia on mortality.
The competing-risks proportional hazards model was
first fitted including all the potential confounders se-
lected in the univariate analyses, hyponatremia, ACLF
and the interaction of the two main factors (Table 3).
The interaction between hyponatremia and ACLF was
not statistically significant (P = 0.53), thus the effects of
hyponatremia and ACLF were assumed as independent
and adjusted for the potential confounders in order toobtain the final model estimates. After adjusting for con-
founding variables, hyponatremia without ACLF was
found to nearly double the risk of dying at 90 days, while
for patients with both ACLF and hyponatremia the rela-
tive risk was nearly seven times higher than for patients
without either factor (Table 3). The corresponding sur-
vival curves of patients with and without ACLF according
to the presence of hyponatremia at inclusion are shown in
Figure 2. In patients without ACLF, the presence of
hyponatremia was associated with a poor prognosis. In
fact, patients with hyponatremia without ACLF had a
90-day survival probability of 70.5% compared to 88.9%
in patients without ACLF and without hyponatremia
(P <0.001). Moreover, the presence of hyponatremia
was associated with even a poorer prognosis in patients
with ACLF. Patients with ACLF without hyponatremia
had a 90-day survival probability of 58.7%, compared
Table 2 Characteristics of patients with acute-on-chronic liver failure (ACLF) according to presence of hyponatremia at
study inclusion
Patients? characteristics Patients without hyponatremia
(Na > = 130 mEq/L) (N = 228)
Patients with hyponatremia
(Na <130 mEq/L) (N = 73)
P value
Age (years) 56.1 (11.5) 53.7 (11.4) 0.12
Male sex 148 (64.9) 45 (61.6) 0.61
Alcoholic cirrhosis 136 (59.6) 39 (53.4) 0.54
Previous decompensations* 161 (74.9) 56 (82.4) 0.20
Complications at admission**
Bacterial infections 72 (31.9) 27 (37.0) 0.42
Hepatic encephalopathy 130 (57.0) 44 (61.1) 0.54
Ascites 173 (76.2) 61 (85.9) 0.08
Gastrointestinal bleeding 36 (15.8) 5 (6.9) 0.05
Clinical and laboratory data
Mean arterial pressure (mm/Hg) 79.7 (13.0) 77.3 (12.1) 0.15
Heart rate (beats/min) 83.5 (19.0) 83.3 (16.8) 0.94
Serum bilirubin (mg/dL) 11.0 (11.2) 14.6 (11.3) 0.02
International normalized ratio 2.1 (0.9) 2.1 (0.9) 0.90
AST (U/L) 116 (198) 233 (412) 0.03
ALT (U/L) 57 (98) 95(165) 0.10
GGT (U/L) 139 (151) 153 (194) 0.62
Serum creatinine (mg/dL) 2.2 (1.5) 2.8 (1.9) 0.01
Serum sodium (mEq/L) 136 (4.6) 125 (3.5) <0.001
Serum potassium (mEq/L) 4.2 (0.8) 4.7 (1.1) <0.001
Leukocyte count (?10 9 cells/L) 9.5 (6.1) 12.1 (7.0) 0.003
Plasma C-reactive protein (mg/L) 40.9 (44.3) 42.0 (36.2) 0.86
MELD score 26.6 (7.0) 30.0 (6.6) <0.001
Child-Pugh score 10.9 (2.1) 11.6 (2.1) 0.0341
CLIF-SOFA score*** 10.1 (3.3) 11.6 (3.1) 0.0034
Data are means (standard deviation (SD)) or number of patients (%). *In the three months prior to study inclusion; **between hospital admission and study
inclusion; ***CLIF-SOFA: a score that evaluates the severity of cirrhosis by assessing function of six different organs and correlates with prognosis. See reference
[13]. AST: aspartate transaminase; ALT: alanine transaminase; GGT: gamma-glutamyl transferase; MELD: model for end-stage liver disease; CLIF-SOFA: chronic liver
failure-sequential organ failure assessment.
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(P = 0.001). Similar differences in survival were observed
when both patients with hyponatremia at inclusion and
during hospitalization were considered (Figure S1 in
Additional file 1).Table 3 Assessment of the interaction between acute-on-chro
estimation of the risk of 90-day mortality adjusted by potent
Assessment of ACLF-by-hyponatremia interaction Estimate
Parameter Hazard ratio
(95% CI)*
P value Parame
ACLF at study enrolment 3.99 (2.92-5.44) <0.001 ACLF at
Hyponatremia at study enrolment 2.00 (1.33-3.02) 0.001 Hyponat
Combina
Interaction ACLF-by-hyponatremia 0.83 (0.47-1.48) 0.5300 ACLF/hy
*Hazard ratio estimates from a competing-risks proportional hazards model, adjusti
count, heart rate and serum potassium at study enrolment. CI: confidence interval.Discussion
This study represents an extensive assessment of the in-
fluence of hyponatremia in patients with ACLF. ACLF is
considered a distinct entity apart from decompensated
cirrhosis; it is defined as an abrupt hepatic deteriorationnic liver failure (ACLF) and hyponatremia at inclusion and
ial confounding factors
of the independent effect of ACLF and hyponatremia
ter Hazard ratio
(95% CI)*
P value
study enrolment 3.78 (2.90-4.93) <0.0001
remia at study enrolment 1.81 (1.33-2.47) 0.0002
tion of independent effects:
ponatremia vs. no ACLF/no hyponatremia 6.85 (3.85-12.19) <0.0001
ng for age, presence of ascites, presence of bacterial infections, white cell
Non-ACLF w/out Hyponatremia
Non-ACLF with Hyponatremia
ACLF w/out Hyponatremia
ACLF with Hyponatremia
KM survival curves
(Model-adjusted HR: 1.8; 95%IC: 1.3 ? 2.5)
(Model-adjusted HR: 3.8; 95%IC: 2.9 ? 4.9)
(Model-adjusted HR: 6.9; 95%IC: 3.9 ? 12.2)
88.9%
70.5%
58.7%
35.8%
Figure 2 Transplant-free survival curves in patients with and without acute-on-chronic liver failure (ACLF) according to the presence of
hyponatremia at inclusion. CLIF: chronic liver failure; CLIF-SOFA: chronic liver failure-sequential organ failure assessment; HR: hazard ratio;
MELD: model for end-stage liver disease.
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is usually related to a precipitating event and associated
with increased mortality at three months due to multi-
system organ failure [11-13]. So despite the fact that
hyponatremia is a well-recognized complication of pa-
tients with advanced cirrhosis, a specific analysis of
hyponatremia in patients with ACLF had so far not been
reported. The investigation of this relationship is clinic-
ally relevant, given the important physiological effects of
low serum sodium levels and the well-demonstrated re-
lationship between hyponatremia and survival in the glo-
bal population of patients with decompensated cirrhosis
[4-7,15-19]. In this analysis, we have shown that the
presence of hyponatremia in patients with ACLF influ-
ences outcome. Interestingly, both variables (hyponatre-
mia and ACLF) independently affect this outcome. Thus
the presence of hyponatremia in a patient without ACLF
significantly increases the risk of dying at 90 days, but
when patients with both (ACLF and hyponatremia) are
compared to those without either (ACLF and hyponatre-
mia) then there is an even higher risk of dying at 90 days.
These findings, to our knowledge, have not been re-
ported in this subset of patients.
As expected, and in keeping with previous studies, the
presence of hyponatremia was associated with increased
three-month mortality [15-19]. However, a relevant ob-
servation of this study was that the prognosis of patients
with ACLF was strongly dependent on the presence or
absence of concomitant hyponatremia. In fact, patients
with ACLF plus hyponatremia had very low three-month survival expectancy compared to that of patients
with ACLF without hyponatremia (35.8% vs. 58.7%, re-
spectively; P <0.001). Similar findings were also observed
if patients who developed ACLF during hospitalization
were taken into consideration (44.5% vs. 61.5%, respect-
ively; P <0.001). On the other hand, in patients without
ACLF, the presence or absence of hyponatremia also influ-
enced prognosis, in such a way that the group of patients
without ACLF without hyponatremia had an excellent
three-month survival, near 90%, much better than that of
patients without ACLF but with hyponatremia.
For many years hyponatremia in patients with cirrho-
sis has been clearly described as an independent risk fac-
tor for mortality [4-7]. The mechanisms that drive this
poor prognosis are likely related to its occurrence along
with other complications of cirrhosis. In a survey study
of 997 cirrhotic patients, Angeli et al. demonstrated a
prevalence of serum sodium ≤130 mmol/L of 21.6% [20].
This patient subgroup had a significantly higher inci-
dence of hepatic encephalopathy (odds ratio (OR) 3.40;
2.35 to 4.92), hepatorenal syndrome (OR 3.45; 2.04 to
5.82), and spontaneous bacterial peritonitis (OR 2.36;
1.41 to 3.93). It is estimated that patients with cirrhosis
and hyponatremia have a 25-50% probability of survival at
one year and 23% at five years [4,5]. In contrast to what
occurs in cirrhosis in patients with ACLF, hyponatremia
portends a 35% probability of survival at three months.
The mechanistic reason as to why such as difference exists
has not been properly assessed, but it is known that in
ACLF increasing organ failures certainly drive prognosis,
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sarily occur.
Although not a primary endpoint, we found an interest-
ing and previously unreported association between hypo-
natremia and leukocyte count in these patients. These
findings do not reflect the aim of the study, which was to
focus on the outcome of patients with ACLF and hypona-
tremia. Nonetheless two variables, ACLF and leukocyte
count, were associated with the presence of hyponatremia
in this large cohort of patients. This relationship between
leukocyte count and hyponatremia appeared to be inde-
pendent from bacterial infections, because among patients
without bacterial infections, those with hyponatremia had
significantly higher leukocyte count than that of patients
without hyponatremia. This relationship is intriguing and
may have pathophysiological relevance. Alternatively, it
could also be possible that cytokines may interfere directly
in kidney water metabolism, causing an impaired water
excretion as suggested in other disease states [21,22]. In
patients without cirrhosis, development of hyponatremia
has been associated with inflammatory diseases such men-
ingitis, pneumonia, tuberculosis, encephalitis, human
immunodeficiency virus infection, and malaria [23,24].
However, this needs to be properly studied in patients
with cirrhosis and also in those with ACLF.
Conclusions
The results of the current study show that there is an im-
portant association between hyponatremia and ACLF.
Hyponatremia is not only a prognostic marker in patients
with ACLF, but influences the outcome of these patients.
Mortality rates are clearly different among patients with
ACLF with and without hyponatremia. In patients with
ACLF prognosis is clearly dependent on its association
with hyponatremia.
Additional file
Additional file 1: Figure S1. Transplant-free survival curves in patients
with and without ACLF according to the presence of hyponatremia during
hospitalization.
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